MA43799A - Composés de 2-oxindole - Google Patents
Composés de 2-oxindoleInfo
- Publication number
- MA43799A MA43799A MA043799A MA43799A MA43799A MA 43799 A MA43799 A MA 43799A MA 043799 A MA043799 A MA 043799A MA 43799 A MA43799 A MA 43799A MA 43799 A MA43799 A MA 43799A
- Authority
- MA
- Morocco
- Prior art keywords
- oxindole compounds
- oxindole
- compounds
- Prior art date
Links
- 150000005623 oxindoles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662280969P | 2016-01-20 | 2016-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43799A true MA43799A (fr) | 2021-03-31 |
Family
ID=59314376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043799A MA43799A (fr) | 2016-01-20 | 2017-01-18 | Composés de 2-oxindole |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20170204087A1 (fr) |
| EP (1) | EP3405455B1 (fr) |
| JP (1) | JP6898334B6 (fr) |
| KR (1) | KR102799183B1 (fr) |
| CN (1) | CN108698991B (fr) |
| AR (1) | AR107398A1 (fr) |
| AU (1) | AU2017209023B2 (fr) |
| BR (1) | BR112018014666B1 (fr) |
| ES (1) | ES2985738T3 (fr) |
| IL (1) | IL260635B (fr) |
| MA (1) | MA43799A (fr) |
| MX (1) | MX378739B (fr) |
| NZ (1) | NZ744468A (fr) |
| RU (1) | RU2743747C2 (fr) |
| SG (1) | SG11201806153QA (fr) |
| TW (1) | TWI729059B (fr) |
| WO (1) | WO2017127409A1 (fr) |
| ZA (1) | ZA201804966B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018014666B1 (pt) | 2016-01-20 | 2024-01-02 | Chemocentryx, Inc | Compostos de 2-oxindol, seu uso e composição farmacêutica |
| US20230041197A1 (en) * | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| ES3068390T3 (en) | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| US12493244B2 (en) * | 2019-10-21 | 2025-12-09 | Shin-Etsu Chemical Co., Ltd. | Photosensitive resin composition, photosensitive dry film, and pattern formation method |
| CA3156298A1 (fr) * | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combinaison d'un antagoniste de cxcr7 avec un modulateur du recepteur s1p1 |
| WO2023057589A1 (fr) * | 2021-10-06 | 2023-04-13 | Virothera Ltd | Nouveau régulateur immunitaire |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| FR2714378B1 (fr) * | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
| WO1997026242A1 (fr) | 1996-01-17 | 1997-07-24 | Taiho Pharmaceutical Co., Ltd. | Derives de 3-(bis-phenylmethylene substitue) oxindole |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| FR2807038B1 (fr) * | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| JP2006508893A (ja) | 2002-03-15 | 2006-03-16 | イーライ・リリー・アンド・カンパニー | ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−２−オン誘導体 |
| AU2003298661B2 (en) * | 2002-11-18 | 2007-05-10 | Chemocentryx, Inc. | Aryl sulfonamides |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| EP2073806B1 (fr) * | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Utilisation de composés de spiro-oxindole comme agents thérapeutiques |
| FR2909668B1 (fr) * | 2006-12-12 | 2009-01-23 | Sanofi Aventis Sa | Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique |
| MX2009008425A (es) * | 2007-02-06 | 2009-08-17 | Novartis Ag | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. |
| HRP20150882T1 (hr) * | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| WO2011069298A1 (fr) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de cyclopropane indolinone |
| DK2820006T3 (da) * | 2012-02-29 | 2017-11-06 | Chemocentryx Inc | Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
| BR112018014666B1 (pt) | 2016-01-20 | 2024-01-02 | Chemocentryx, Inc | Compostos de 2-oxindol, seu uso e composição farmacêutica |
-
2017
- 2017-01-18 BR BR112018014666-8A patent/BR112018014666B1/pt active IP Right Grant
- 2017-01-18 TW TW106101711A patent/TWI729059B/zh active
- 2017-01-18 KR KR1020187023830A patent/KR102799183B1/ko active Active
- 2017-01-18 CN CN201780007677.XA patent/CN108698991B/zh active Active
- 2017-01-18 RU RU2018129849A patent/RU2743747C2/ru active
- 2017-01-18 JP JP2018537816A patent/JP6898334B6/ja active Active
- 2017-01-18 EP EP17741838.1A patent/EP3405455B1/fr active Active
- 2017-01-18 NZ NZ744468A patent/NZ744468A/en unknown
- 2017-01-18 WO PCT/US2017/013899 patent/WO2017127409A1/fr not_active Ceased
- 2017-01-18 ES ES17741838T patent/ES2985738T3/es active Active
- 2017-01-18 US US15/408,896 patent/US20170204087A1/en not_active Abandoned
- 2017-01-18 SG SG11201806153QA patent/SG11201806153QA/en unknown
- 2017-01-18 MA MA043799A patent/MA43799A/fr unknown
- 2017-01-18 AU AU2017209023A patent/AU2017209023B2/en active Active
- 2017-01-18 MX MX2018008895A patent/MX378739B/es unknown
- 2017-01-19 AR ARP170100150A patent/AR107398A1/es active IP Right Grant
-
2018
- 2018-03-07 US US15/914,900 patent/US10421748B2/en active Active
- 2018-07-17 IL IL260635A patent/IL260635B/en active IP Right Grant
- 2018-07-24 ZA ZA2018/04966A patent/ZA201804966B/en unknown
-
2019
- 2019-07-29 US US16/524,618 patent/US10759789B2/en active Active
-
2020
- 2020-07-17 US US16/932,114 patent/US11434230B2/en active Active
-
2022
- 2022-08-01 US US17/816,614 patent/US12139475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3691623A4 (fr) | Composés de benzosulfonyle | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| NO2024054I1 (no) | Ciltacabtagene autoleucel | |
| MA49701A (fr) | Composés immunomodulateurs | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3474845A4 (fr) | Composés immunomodulateurs | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| EP3523306A4 (fr) | Composés spirocycliques | |
| ME03419B (fr) | Composés dihydroisoquinolinone substitués | |
| MA44233A (fr) | Nouveaux composés | |
| MA42293A (fr) | Composés antibactériens | |
| MA44020A (fr) | Composés antitumoraux | |
| MA41614A (fr) | Composés antiviraux | |
| EP3445750A4 (fr) | Composés thérapeutiques | |
| EP3551176A4 (fr) | Composés hétérocycliques antidiabétiques | |
| EP3383420A4 (fr) | Conjugués de composés de tubulysine quaternisés | |
| EP3436003A4 (fr) | Composés bicycliques antidiabétiques | |
| EP3497134A4 (fr) | Composés de modulation immunitaire | |
| PT4039675T (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| EP3464336A4 (fr) | Composés | |
| EP3405455A4 (fr) | Composés de 2-oxindole | |
| EP3728289A4 (fr) | Composés optimisés | |
| MA49621A (fr) | Composés bifonctionnels | |
| EP3709995A4 (fr) | Composés bicycliques antidiabétiques | |
| EP3309163A4 (fr) | Dérivé de dihydropyrrolopyrazole substitué |